2 results
Approved WMOCompleted
To determine the within and between variability of pharmacokinetic (PK) profiles in patients treated with DOACs in daily practice
Not approvedWill not start
The primary objective of this study is to evaluate the proportion of patients achieving FXI inhibition * 80% at trough (Day 91) after monthly dosing at 3 dose levels of MAA868.